S&P Futures
5,878.00 -18.25 (-0.31%) Dow Futures
43,061.00 -116.00 (-0.27%) Nasdaq Futures
20,443.75 -75.75 (-0.37%) Russell 2000 Futures
2,241.90 -13.60 (-0.60%) Crude Oil
70.20 -0.36 (-0.51%) Gold
2,750.70 +11.80 (+0.43%)
Adicet Bio, Inc. (ACET)
After hours:
| Previous Close | 1.4500 |
| Open | 1.4600 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.4200 - 1.5100 |
| 52 Week Range | 1.0500 - 3.7700 |
| Volume | |
| Avg. Volume | 522,496 |
| Market Cap | 122.777M |
| Beta (5Y Monthly) | 1.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5200 |
| Earnings Date | Nov 06, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.40 |
TipRanksAdicet Bio Advances FDA-Approved Autoimmune Therapy Trials
Adicet Bio ( (ACET) ) has provided an update. Adicet Bio has received FDA clearance to expand its investigational new drug application, allowing the evaluation of ADI-001 in idiopathic inflammatory myopathy and stiff person syndrome as part of an ongoing Phase 1 trial. This development marks a significant step in Adicet’s efforts to tackle six autoimmune diseases using its gamma delta T cell therapies. Patient enrollment for these conditions is slated to begin in early 2025, with initial clinica
- Business Wire
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
REDWOOD CITY, Calif. & BOSTON, October 16, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has agreed to an amendment to the Company’s Investigational New Drug (IND) application to evaluate ADI-001 in idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) as part of the ongoing Phase 1
